Skip to content
CancerIndex

Loading the knowledge graph…

Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment — knowledge graph · CancerIndex